ASCJ 9

Drug Profile

ASCJ 9

Alternative Names: ASC-J9; Dimethyl curcumin

Latest Information Update: 07 Aug 2015

Price : $50

At a glance

  • Originator AndroScience Corporation
  • Class Alkadienes; Antiacnes; Catechols; Small molecules
  • Mechanism of Action Androgen receptor degradation enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acne vulgaris
  • Preclinical Male pattern baldness; Spinal muscular atrophy; Wounds

Most Recent Events

  • 07 Aug 2015 Phase-II development is ongoing for Acne vulgaris in USA
  • 26 Jan 2011 AndroScience receives Translational Research Grant from the National Institutes of Health for JSC 9 development in Spinal muscular atrophy
  • 26 Jan 2011 ASCJ 9 is still available for licensing as of 26 Jan 2011. http://www.androscience.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top